New insider activity at Rani Therapeutics Holdings ( (RANI) ) has taken place on October 22, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Significant shareholder South Cone Investments Limited Partnership has divested 5,923,000 shares of Rani Therapeutics Holdings stock, amounting to a transaction worth $15,674,430.
Recent Updates on RANI stock
Rani Therapeutics Holdings has seen significant developments recently, impacting its stock price and analyst ratings. The company announced a collaboration with Chugai Pharmaceutical, which is expected to provide non-dilutive financing and validate its RaniPill technology. This partnership, along with a private placement raising $60 million, has led to increased price targets from analysts, reflecting optimism about Rani’s financial and strategic position. Additionally, the company secured a new loan agreement, which may influence its market positioning. However, despite these positive advancements, Rani faces challenges with no revenue, consistent net losses, and high leverage, which are reflected in a bearish technical analysis and negative valuation metrics.
Spark’s Take on RANI Stock
According to Spark, TipRanks’ AI Analyst, RANI is a Underperform.
Rani Therapeutics Holdings’ overall stock score reflects significant financial struggles with no revenue and consistent net losses. The technical analysis shows a bearish trend, and the valuation is challenging with a negative P/E ratio. Strategic advancements in technology and potential partnerships are positive but are overshadowed by financial constraints and high leverage.
To see Spark’s full report on RANI stock, click here.
More about Rani Therapeutics Holdings
YTD Price Performance: 95.21%
Average Trading Volume: 12,853,000
Technical Sentiment Signal: Buy
Current Market Cap: $161.7M